Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.5% – Time to Sell?

Shares of Eli Lilly and Company (NYSE:LLY) fell 1.5% during mid-day trading on Tuesday . The company traded as low as $1,024.08 and last traded at $1,042.6780. 2,791,644 shares were traded during trading, a decline of 18% from the average session volume of 3,391,751 shares. The stock had previously closed at $1,058.56.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial: Novo Nordisk said its next‑gen obesity drug CagriSema failed to demonstrate non‑inferiority vs Lilly’s tirzepatide over 84 weeks — NVO shares plunged and investors see this as reinforcing Lilly’s leadership in the fast‑growing GLP‑1/weight‑loss market. Novo’s stumbles burnish Lilly’s widening lead in weight-loss drugs
• Positive Sentiment: Zepbound KwikPen launch/approval: FDA label expansion and a new multi‑dose KwikPen (one month of doses per device) increases convenience, may improve adherence/retention, and keeps Lilly competitive on pricing and patient experience. Zepbound (tirzepatide) now available in multi-dose KwikPen
• Positive Sentiment: Analyst support: Goldman Sachs (Asad Haider) maintained a Buy rating and left a high price target (~$1,260), reflecting confidence in Lilly’s obesity leadership, diversified pipeline and capital flexibility. Eli Lilly: Conservative 2026 Guide, Diversified Pipeline, and Capital Flexibility Underscore Buy Rating Amid Obesity Leadership
• Positive Sentiment: Pipeline / clinical wins: Positive combo data (Taltz + tirzepatide) and new licensing/trial readouts expand indications and reinforce revenue optionality beyond obesity/diabetes. Eli Lilly expands pipeline with positive trial data and new licensing deal
• Neutral Sentiment: Market positioning note: Some commentary says LLY has recently underperformed the S&P 500 despite the company’s strong fundamentals — a reminder that short‑term moves can reflect index dynamics and sector rotations. Is Eli Lilly Stock Underperforming the S&P 500?
• Neutral Sentiment: Analyst consensus / targets remain elevated (median targets well above current levels), supporting a constructive medium‑term view but also implying expectations are priced in. Eli Lilly rises as rival obesity-drug trial data strengthen tirzepatide’s edge
• Negative Sentiment: Insider/ownership flows: Data show substantial share sales by large holders and frequent insider dispositions in recent periods — a potential headwind for sentiment if selling persists. Eli Lilly rises as rival obesity-drug trial data strengthen tirzepatide’s edge

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on LLY shares. Rothschild & Co Redburn raised their price objective on Eli Lilly and Company from $775.00 to $830.00 and gave the company a “neutral” rating in a research note on Monday, January 26th. Berenberg Bank raised their price objective on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the company a “hold” rating in a research note on Thursday, February 19th. Bank of America decreased their target price on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research report on Monday, December 15th. CICC Research raised their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research report on Wednesday, February 11th. Finally, Scotiabank reissued an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,228.54.

Eli Lilly and Company Stock Down 1.5%

The stock has a 50-day moving average of $1,054.73 and a 200 day moving average of $920.78. The company has a market capitalization of $983.62 billion, a PE ratio of 45.43, a P/E/G ratio of 1.17 and a beta of 0.39. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business’s revenue was up 42.6% compared to the same quarter last year. During the same period last year, the firm posted $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is currently 30.15%.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors have recently bought and sold shares of LLY. Vanguard Group Inc. raised its position in shares of Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. State Street Corp raised its holdings in Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after buying an additional 635,358 shares during the last quarter. Capital Research Global Investors grew its holdings in shares of Eli Lilly and Company by 20.9% during the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Morgan Stanley increased its position in shares of Eli Lilly and Company by 2.7% during the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after acquiring an additional 407,166 shares in the last quarter. Finally, Capital World Investors increased its position in shares of Eli Lilly and Company by 0.4% during the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after acquiring an additional 61,851 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.